H.C. Wainwright lowered the firm’s price target on PolyPid to $14 from $16 and keeps a Buy rating on the shares. The analyst cites equity dilution for the target drop. The recent PIPE financing extends PolyPid’s cash runway into Q3 of 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- PolyPid enrolls 100th patient in SHIELD II phase 3 trial
- PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
- PolyPid Ltd. (PYPD) Q4 Earnings Cheat Sheet
- PolyPid files to sell 6.74M ordinary shares for holders
